Home
Halfdan Sørbye's picture

Halfdan Sørbye

Professor
  • E-mailHalfdan.Sorbye@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Sorbye, Halfdan; Baudin, Eric; Borbath, Ivan; Caplin, Martyn Evan; Chen, Jie; Cwikla, Jaroslaw; Frilling, Andrea; Grossman, Ashley B.; Kaltsas, Gregory; Scarpa, Aldo; Welin, Staffan; Garcia-Carbonero, Rocio. 2019. Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology. 54-62.
  • Hamfjord, Julian; Guren, Tormod Kyrre; Dajani, Olav; Johansen, Julia Sidenius; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per; Lingjærde, Ole Christian; Tveit, Magne Kjell; Kure, Elin Wenche Hegland; Pallisgaard, Niels; Spindler, Karen-Lise Garm. 2019. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Annals of Oncology. 1088-1095.
  • Joranger, Pål; Nesbakken, Arild; Sorbye, Halfdan; Hoff, Geir; Oshaug, Arne; Aas, Eline. 2019. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. European Journal of Health Economics. 1-14.
  • Winther, Stine Brændegaard; Liposits, Gabor Isivan; Skuladottir, Halla; Hofsli, Eva; Shah, Carl-Henrik; Poulsen, Laurids Østergaard; Ryg, Jesper; Österlund, Pia; Berglund, Åke; Qvortrup, Camilla; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per. 2019. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology. 376-388.
  • Carlsen, Esben Andreas; Fazio, Nicola; Granberg, Dan; Grozinsky-Glasberg, Simona; Ahmadzadehfar, Hojjat; Grana, Chiara Maria; Zandee, Wouter T.; Cwikla, Jaroslaw; Walter, Martin A.; Oturai, Peter Sandor; Rinke, Anja; Weaver, Andrew; Frilling, Andrea; Gritti, Sara; Arveschoug, Anne Kirstine; Meirovitz, Amichay; Knigge, Ulrich; Sorbye, Halfdan. 2019. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study. Endocrine-Related Cancer. 227-239.
  • Mezheyeuski, Artur; Pontén, Fredrik; Edqvist, Per-Henrik; Sundström, Magnus; Thunberg, Ulf; Qvortrup, Camilla; Pfeiffer, Per; Sorbye, Halfdan; Glimelius, Bengt; Dragomir, Anca. 2019. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta Oncologica. 1-8.
  • Aasebø, Kristine; Dragomir, Anca; Sundström, Magnus; Mezheyeuski, Artur; Edqvist, Per-Henrik; Eide, Geir Egil; Pontén, Fredrik; Pfeiffer, Per; Glimelius, Bengt; Sorbye, Halfdan. 2019. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. Cancer Medicine. 3623-3635.
  • Sorbye, Halfdan; Baudin, Eric; Perren, Aurel. 2018. The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: Well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinology and metabolism clinics of North America (Print). 683-698.
  • Thomsen, Maria; Skovlund, Eva; Sorbye, Halfdan; Bolstad, Nils; Nustad, Kjell Johannes; Glimelius, Bengt; Pfeiffer, Per; Kure, Elin Wenche Hegland; Johansen, Julia S.; Tveit, Magne Kjell; Christoffersen, Thoralf; Guren, Tormod Kyrre. 2018. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. British Journal of Cancer. 1609-1616.
  • Ali, Abir Salwa; Grönberg, Malin; Langer, Seppo Wang; Ladekarl, Morten; Hjortland, Geir Olav; Vestermark, Lene Weber; Österlund, Pia; Welin, Staffan; Grønbæk, Henning; Knigge, Ulrich; Sorbye, Halfdan; Janson, Eva Tiensuu. 2018. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology.
  • Bjørnelv, Gudrun Maria Waaler; Dueland, Svein; Line, Pål Dag; Joranger, Pål; Fretland, Åsmund Avdem; Edwin, Bjørn; Sorbye, Halfdan; Aas, Eline. 2018. Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. British Journal of Surgery.
  • Goey, Kaitlyn K.H.; Sorbye, Halfdan; Glimelius, Bengt; Adams, Richard A; Andre, Thierry; Arnold, Dirk; Berlin, Jordan D; Bodoky, Gyorgy; de Gramont, Aimery; Diaz-Rubio, Eduardo; Eng, Cathy; Falcone, Alfredo; Grothey, Axel; Heinemann, Volker; Hochster, Howard S; Kaplan, Richard S; Kopetz, Scott; Labianca, Roberto; Lieu, Christopher H; Meropol, Neal J; Price, Timothy J; Schilsky, Richard L; Schmoll, Hans-Joachim; Shacham-Shmueli, Einat; Shi, Qian; Sobrero, Alberto F; Souglakos, John; Van Cutsem, Eric; Zalcberg, John R.; van Oijen, Martijn G.H.; Punt, Cornelis J.A.; Koopman, Miriam. 2018. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer. 35-45.
  • Dasari, Arvind; Mehta, Kathan; Byers, Lauren Averett; Sorbye, Halfdan; Yao, James C. 2018. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 807-815.
  • Mezheyeuski, Artur; Strell, Carina; Hrynchyk, Ina; Guren, Tormod Kyrre; Dragomir, Anca; Doroshenko, Tatyana; Pashkova, Oksana; Gorgun, Julia; Ruksha, Kseniya; Pfeiffer, Per; Kure, Elin Wenche Hegland; Sorbye, Halfdan; Edler, David; Martling, Anna; Glimelius, Bengt; Östman, Arne; Portyanko, Anna. 2017. Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Archiv. 1-11.
  • Galleberg, Renate Berget; Knigge, Ulrich Peter; Tiensuu Janson, Eva M.; Vestermark, Lene Weber; Haugvik, Sven-Petter; Ladekarl, Morten; Langer, Seppo Wang; Grønbæk, Henning; Österlund, Pia; Hjortland, Geir Olav; Assmus, Jörg; Tang, Laura; Perren, Aurel A.; Sorbye, Halfdan. 2017. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology. 1682-1689.
  • Winther, Stine Brændegaard; Österlund, Pia; Berglund, Åke; Glimelius, Bengt; Qvortrup, Camilla; Sorbye, Halfdan; Pfeiffer, Per. 2017. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer.
  • Angelsen, Jon-Helge; Horn, Arild; Sorbye, Halfdan; Eide, Geir Egil; Løes, Inger Marie; Viste, Asgaut. 2017. Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. British Journal of Surgery. 580-589.
  • Labori, Knut Jørgen; Lassen, Kristoffer; Hoem, Dag; Grønbech, Jon Erik; Søreide, Jon Arne; Mortensen, Kim Erlend; Smaaland, Rune; Sorbye, Halfdan; Verbeke, Caroline Sophie; Dueland, Svein. 2017. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. BMC Surgery.
  • Siesing, Christina; Sorbye, Halfdan; Dragomir, Anca; Pfeiffer, Per; Qvortrup, Camilla; Pontén, Fredrik; Jirström, Karin; Glimelius, Bengt; Eberhard, Jakob. 2017. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLOS ONE. 1-13.
  • Thomsen, Maria; Guren, Marianne; Skovlund, Eva; Glimelius, Bengt; Hjermstad, Marianne Jensen; Johansen, Julia S.; Kure, Elin Wenche Hegland; Sorbye, Halfdan; Pfeiffer, Per; Christoffersen, Thoralf; Guren, Tormod Kyrre; Tveit, Magne Kjell. 2017. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. European Journal of Cancer. 26-35.
  • Ali, Abir Salwa; Grönberg, Malin; Federspiel, Birgitte; Scoazec, Jean-Yves; Hjortland, Geir Olav; Grønbæk, Henning; Ladekarl, Morten; Langer, Seppo W.; Welin, Staffan; Vestermark, Lene Weber; Arola, Johanna; Österlund, Pia; Knigge, Ulrich; Sorbye, Halfdan; Grimelius, Lars; Janson, Eva Tiensuu. 2017. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLOS ONE. 1-15.
  • Perren, Aurel A.; Couvelard, Anne; Scoazec, Jean-Yves; Costa, Frederico; Borbath, Ivan; Delle Fave, Gianfranco; Gorbounova, Vera; Gross, David; Grossman, Ashley B.; Jensen, Robert T; Kulke, Matthew; Öberg, Kjell; Rindi, Guido; Sorbye, Halfdan; Welin, Staffan. 2017. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification. Neuroendocrinology. 196-200.
  • Garcia-Carbonero, Rocio; Rinke, Anja; Valle, Juan W; Fazio, Nicola; Caplin, Martyn Evan; Gorbounova, Vera; O'Connor, Juan; Eriksson, Barbro; Sorbye, Halfdan; Kulke, Matthew; Chen, Jie; Falkerby, Jenny; Costa, Frederico; De Herder, Wouter; Lombard-Bohas, Catherine; Pavel, Marianne. 2017. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. Neuroendocrinology. 281-294.
  • Pavel, Marianne; Valle, Juan W; Eriksson, Barbro; Rinke, Anja; Caplin, Martyn Evan; Chen, Jie; Costa, Frederico; Falkerby, Jenny; Fazio, Nicola; Gorbounova, Vera; De Herder, Wouter; Kulke, Matthew; Lombard-Bohas, Catherine; O'Connor, Juan; Sorbye, Halfdan; Garcia-Carbonero, Rocio. 2017. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. Neuroendocrinology. 266-280.
  • Guren, Tormod Kyrre; Thomsen, Maria; Kure, Elin H.; Sorbye, Halfdan; Glimelius, Bengt; Pfeiffer, Per; Sigurdsson, Fridbjörn; Lothe, Inger Marie Bowitz; Larsen, Astrid Marie; Skovlund, Eva; Christoffersen, Thoralf; Tveit, Magne Kjell. 2017. Cetuximab in treatment of metastatic colorectal cancer: Final survival analyses and extended RAS data from the NORDIC-VII study. British Journal of Cancer. 1271-1278.
  • Dumanski, Jan P.; Rasi, Chiara; Björklund, Peyman; Davies, Hanna; Ali, Abir S.; Grönberg, Malin; Welin, Staffan; Sorbye, Halfdan; Grønbæk, Henning; Cunningham, Janet L.; Forsberg, Lars A.; Lind, Lars; Ingelsson, Erik; Stålberg, Peter; Hellman, Per; Janson, Eva Tiensuu. 2017. A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. Endocrine-Related Cancer. 427-443.
  • Tarpgaard, Line Schmidt; Ørum-Madsen, Maj Sofie; Christensen, Ib Jarle; Nordgaard, Cathrine; Noer, Julie; Guren, Tormod Kyrre; Glimelius, Bengt; Sorbye, Halfdan; Andersen, Tone Ikdahl; Kure, Elin H.; Tveit, Magne Kjell; Nielsen, Hans Jørgen; Pfeiffer, Per; Brünner, Nils; Moreira, José M.A. 2016. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. OncoTarget. 59441-59457.
  • Mezheyeuski, Artur; Lindh, Maja Bradic; Guren, Tormod Kyrre; Dragomir, Anca; Pfeiffer, Per; Kure, Elin H.; Andersen, Tone Ikdahl; Skovlund, Eva; Corvigno, Sara; Strell, Carina; Pietras, Kristian; Pontén, Fredrik; Mulder, Jan; Qvortrup, Camilla; Portyanko, Anna; Tveit, Magne Kjell; Glimelius, Bengt; Sorbye, Halfdan; Ostman, Arne. 2016. Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. OncoTarget. 41948-41958.
  • Haugvik, Sven-Petter; Janson, Eva Tiensuu; Osterlund, Pia; Langer, Seppo W; Falk, Ragnhild Sørum; Labori, Knut Jørgen; Vestermark, Lene Weber; Grønbæk, Henning; Gladhaug, Ivar Prydz; Sorbye, Halfdan. 2016. Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Annals of Surgical Oncology. 1721-1728.
  • Sveen, Anita; Løes, Inger Marie; Alagaratnam, Sharmini; Nilsen, Gro; Høland, Maren; Lingjærde, Ole Christian; Sorbye, Halfdan; Berg, Kaja Christine Graue; Horn, Arild; Angelsen, Jon-Helge; Knappskog, Stian; Lønning, Per Eystein; Lothe, Ragnhild A. 2016. Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genetics. 22 pages.
  • Thomsen, Maria; Kersten, Christian; Sorbye, Halfdan; Skovlund, Eva; Glimelius, Bengt; Pfeiffer, Per; Johansen, Julia S.; Kure, Elin H.; Andersen, Tone Ikdahl; Tveit, Magne Kjell; Christoffersen, Thoralf; Guren, Tormod Kyrre. 2016. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. OncoTarget. 75013-75022.
  • Løes, Inger Marie; Immervoll, Heike; Sorbye, Halfdan; Angelsen, Jon-Helge; Horn, Arild; Knappskog, Stian; Lønning, Per Eystein. 2016. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. International Journal of Cancer. 647-656.
  • Winther, Stine Brændegaard; Zubcevic, Kanita; Qvortrup, Camilla; Vestermark, Lene Weber; Jensen, Helle Anita; Krogh, Merete; Sorbye, Halfdan; Pfeiffer, Per. 2016. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. Acta Oncologica. 881-885.
  • Garcia-Carbonero, Rocio; Sorbye, Halfdan; Baudin, Eric; Raymond, Eric; Wiedenmann, Bertram; Niederle, Bruno; Sedláčková, Eva; Toumpanakis, Christos G.; Anlauf, Martin; Ćwikła , Jarosław B.; Caplin, Martyn Evan; O'Toole, Dermot; Perren, Aurel A. 2016. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 186-194.
  • Österlund, Pia; Sorbye, Halfdan; Pfeiffer, Per; Johnsson, Anders; Rodrigues, Filipe; Furneri, Gianluca. 2016. Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. Journal of Cancer Policy. 12-22.
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 172-181.
  • Poulsen, Laurids Ø.; Qvortrup, Camilla; Pfeiffer, Per; Yilmaz, Mette; Falkmer, Ursula; Sorbye, Halfdan. 2015. Review on adjuvant chemotherapy for rectal cancer-why do treatment guidelines differ so much? Acta Oncologica. 437-446.
  • Tanis, Erik; Julié, Catherine; Emile, Jean-Francois; Mauer, Murielle; Nordlinger, Bernard; Aust, Daniela; Roth, Arnaud; Lutz, Manfred P.; Gruenberger, Thomas; Wrba, Fritz; Sorbye, Halfdan; Bechstein, Wolf; Schlag, Peter; Fisseler, Annette; Ruers, Theo. 2015. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. European Journal of Cancer. 2708-2717.
  • Angelsen, Jon-Helge; Viste, Asgaut; Løes, Inger Marie; Eide, Geir Egil; Hoem, Dag; Sorbye, Halfdan; Horn, Arild. 2015. Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. World Journal of Surgical Oncology.
  • Joranger, Pål; Nesbakken, Arild; Hoff, Geir; Sorbye, Halfdan; Oshaug, Arne; Aas, Eline. 2015. Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. Medical decision making. 255-265.
  • Pfeiffer, Per; Sorbye, Halfdan; Qvortrup, Camilla; Karlberg, Mia; Kersten, Christian; Vistisen, Kirsten; Lindh, Birgitta; Bjerregaard, Jon Kroll; Glimelius, Bengt. 2015. Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. Clinical colorectal cancer. 170-176.
  • Tarpgaard, Line Schmidt; Christensen, Ib J.; Høyer-Hansen, Gunilla; Lund, Ida K.; Guren, Tormod Kyrre; Glimelius, Bengt; Sorbye, Halfdan; Tveit, Magne Kjell; Nielsen, Hans Jørgen; Moreira, José M.A.; Pfeiffer, Per; Brünner, Nils. 2015. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. International Journal of Cancer. 2470-2477.
  • Sorbye, Halfdan; Dragomir, Anca; Sundström, Magnus; Pfeiffer, Per; Thunberg, Ulf; Bergfors, Monica; Aasebø, Kristine Øvreås; Eide, Geir Egil; Pontén, Fredrik; Qvortrup, Camilla; Glimelius, Bengt. 2015. High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLOS ONE.
  • Tarpgaard, Line Schmidt; Guren, Tormod Kyrre; Glimelius, Bengt; Christensen, Ib J.; Pfeiffer, Per; Kure, Elin H.; Sorbye, Halfdan; Andersen, Tone Ikdahl; Yilmaz, Mette; Johansen, Julia S.; Tveit, Magne Kjell. 2014. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: Results from the NORDIC VII Study. PLOS ONE.
  • Janson, Eva Tiensuu; Sorbye, Halfdan; Welin, Staffan; Federspiel, Birgitte; Grønbæk, Henning; Hellman, Per; Ladekarl, Morten; Langer, Seppo W.; Mortensen, Jann; Schalin-Jäntti, Camilla; Sundin, Anders; Sundlöv, Anna; Thiis-Evensen, Espen; Knigge, Ulrich. 2014. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncologica. 1284-1297.
  • Tanis, Erik; Nordlinger, Bernard; Mauer, Murielle; Sorbye, Halfdan; Van Coevorden, Frits; Gruenberger, Thomas; Schlag, Peter Michael; Punt, Cornelis J.A.; Ledermann, Jonathan A; Ruers, Theo Jacques Marie. 2014. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. European Journal of Cancer. 912-919.
  • Sorbye, Halfdan; Welin, Staffan; Langer, Seppo W.; Vestermark, Lene Weber; Holt, Nanna; Osterlund, Pia; Dueland, Svein; Hofsli, Eva; Guren, Marianne; Ohrling, Katarina; Birkemeyer, Elke; Thiis-Evensen, Espen; Biagini, Matteo; Grønbæk, Henrik; Soveri, Leena-Marja; Olsen, Ingrid Holst; Federspiel, Birgitte; Assmus, Jørg; Janson, Eva T.; Knigge, Ulrich. 2013. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology. 152-160.
  • Nordlinger, Bernard; Sorbye, Halfdan; Glimelius, Bengt; Poston, Graeme J.; Schlag, Peter M.; Rougier, Philippe; Bechstein, Wolf O.; Primrose, John N.; Walpole, Euan T.; Finch-Jones, Meg; Jaeck, Daniel; Mirza, Darius; Parks, Rowan W.; Mauer, Murielle; Tanis, Erik; Van Cutsem, Eric; Scheithauer, Werner; Gruenberger, Thomas. 2013. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. The Lancet Oncology. 1208-1215.
  • Sorbye, Halfdan; Småstuen, Milada Cvancarova; Qvortrup, Camilla; Pfeiffer, Per; Glimelius, Bengt. 2013. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Annals of Oncology. 2354-2360.
  • Trønnes, Håvard; Haugland, Hans Kristian; Bekassy, Albert N.; Helle, Svein Inge; Sorbye, Halfdan. 2012. Small Cell Lung Cancer in a 14-Year-Old Girl. Journal of Pediatric Hematology/Oncology. E86-E88.
  • Sorbye, Halfdan; Mauer, Murielle; Gruenberger, Thomas; Glimelius, Bengt; Poston, Graeme J.; Schlag, Peter M.; Rougier, Philippe; Bechstein, Wolf O.; Primrose, John N.; Walpole, Euan T.; Finch-Jones, Meg; Jaeck, Daniel; Mirza, Darius; Parks, Rowan W.; Collette, Laurence; Van Cutsem, Eric; Scheithauer, Werner; Lutz, Manfred P.; Nordlinger, Bernard. 2012. Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). Annals of Surgery. 534-539.
  • Tveit, Magne Kjell; Guren, Tormod Kyrre; Glimelius, Bengt; Pfeiffer, Per; Sorbye, Halfdan; Pyrhonen, Seppo; Sigurðsson, Friðbjörn; Kure, Elin H.; Andersen, Tone Ikdahl; Skovlund, Eva; Fokstuen, Tone; Hansen, Flemming; Hofsli, Eva; Birkemeyer, Elke; Johnsson, Anders; Starkhammar, Hans; Yilmaz, Mette Karen; Keldsen, Nina; Erdal, Anne Berit Rødal; Dajani, Olav; Dahl, Olav; Christoffersen, Thoralf. 2012. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. Journal of Clinical Oncology. 1755-1762.
  • Cavalli-Björkman, Nina; Qvortrup, Camilla; Sebjørnsen, Sigrunn; Pfeiffer, Per; Wentzel-Larsen, Tore; Glimelius, Bengt; Sorbye, Halfdan. 2012. Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. British Journal of Cancer. 189-194.
  • Kjersem, Janne Beathe; Andersen, Tone Ikdahl; Guren, Tormod Kyrre; Skovlund, Eva; Sorbye, Halfdan; Hamfjord, Julian; Pfeiffer, Per; Glimelius, Bengt; Kersten, Christian; Solvang, Hiroko Kato; Tveit, Magne Kjell; Kure, Elin H. 2012. Let-7 miRNA-binding site polymorphism in the KRAS 3 ' UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. BMC Cancer.
  • Roy, Arunabha; Cunningham, David; Hawkins, Robert; Sorbye, Halfdan; Adenis, Antoine; Barcelo, Jose Ramon; Lopez-Vivanco, Guillermo; Adler, Guido; Canon, Jean-Luc; Lofts, Fiona; Castanon, C.; Fonseca, E.; Rixe, Olivier; Aparicio, Jorge; Cassinello, Javier; Nicolson, Marianne; Mousseau, Mireille; Schalhorn, Andreas; D'Hondt, Lionel; Kerger, Joseph; Hossfeld, Dieter K.; García-Girón, Carlios; Rodriguez, R.; Schöffski, Patrick; Misset, Jean-Louis. 2012. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British Journal of Cancer. 435-441.
  • Fassnacht, Martin; Terzolo, Massimo; Allolio, Bruno; Baudin, Eric; Haak, Harm; Berruti, Alfredo; Welin, Staffan; Schade-Brittinger, Carmen; Lacroix, André; Jarzab, Barbara; Sorbye, Halfdan; Torpy, David J.; Stepan, Vinzenz; Schteingart, David E.; Arlt, Wiebke; Kroiss, Matthias; Leboulleux, Sophie; Sperone, Paola; Sundin, Anders; Hermsen, Ilse; Hahner, Stefanie; Willenberg, Holger S.; Tabarin, Antoine; Quinkler, Marcus; de la Fouchardiere, Christelle; Schlumberger, Martin; Mantero, Franco; Weismann, Dirk; Beuschlein, Felix; Gelderblom, Hans; Wilmink, Hanneke; Sender, Monica; Edgerly, Maureen; Kenn, Werner; Fojo, Tito; Müller, Hans-Helge; Skogseid, Britt. 2012. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine. 2189-2197.
  • Glimelius, Bengt; Garmo, Hans; Berglund, Åke; Fredriksson, Lennart A.; Berglund, Mattias; Kohnke, Hugo; Byström, Pär; Sørbye, Halfdan; Wadelius, Mia. 2011. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. The Pharmacogenomics Journal. 61-71.
  • Welin, Staffan; Sørbye, Halfdan; Sebjørnsen, Sigrunn; Knappskog, Stian; Busch, Christian; Öberg, Kjell. 2011. Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 4617-4622.
  • Janson, ET; Sørbye, Halfdan; Welin, S; Federspiel, B; Grønbæk, H; Hellman, P; Mathisen, Øystein; Mortensen, J; Sundin, S; Thiis-Evensen, Espen; Välimäki, M; Öberg, Kjell; Knigge, U. 2010. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncologica. 740-756.
  • Sørbye, Halfdan; Pfeiffer, P; Cavalli-Bjorkman, N; Qvortrup, C; Holsen, MH; Wentzel-Larsen, T; Glimelius, B. 2009. Clinical Trial Enrollment, Patient Characteristics, and Survival Differences in Prospectively Registered Metastatic Colorectal Cancer Patients. Cancer. 4679-4687.
  • Sørbye, Halfdan. 2008. Prognostic clinical factors in metastatic colorectal cancer. Advances in Gastrointestinal Cancers. 6-8.
  • Nordlinger, Bernard; Sørbye, Halfdan; Glimelius, Bengt; Poston, Graeme J.; Schlag, Peter M.; Rougier, Philippe; Bechstein, Wolf O.; Primrose, John N.; Walpole, Euan T.; Finch-Jones, Meg; Jaeck, Daniel; Mirza, Darius; Parks, Rowan W.; Collette, Laurence; Praet, Michel; Bethe, Ulrich; Van Cutsem, Eric; Scheithauer, Werner; Gruenberger, Thomas. 2008. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. The Lancet. 1007-1016.
  • Qvortrup, C; Yilmaz, M; Øgreid, Dagfinn; Berglund, A; Balteskard, L; Ploen, J.; Fokstuen, T; Starkhammar, H; Sørbye, Halfdan; Tveit, KM; Pfeiffer, P. 2008. Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Annals of Oncology. 1154-1159.
  • Glimelius, Bengt; Sørbye, Halfdan; Balteskard, L; Byström, P; Pfeiffer, P; Tveit, KM; Heikkilä, R; Keldsen, N; Albertsson, M; Starkhammar, H; Garmo, H; Berglund, Å. 2008. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Annals of Oncology. 909-914.
  • Hovdenak, Nils; Sørbye, Halfdan; Dahl, Olav. 2005. SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clinical Oncology. 485-491.
  • Sørbye, Halfdan; Dahl, Olav. 2004. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncologica. 495-498.
  • Sørbye, Halfdan; Glimelius, Bengt; Berglund, Å; Fokstuen, T; Tveit, Kjell Magne; Brændengen, M; Øgreid, D; Dahl, Olav. 2004. Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 31-38.
  • Hovdenak, Nils; Karlsdottir, Åsa; Sørbye, Halfdan; Dahl, Olav. 2003. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncologica. 741-748.
  • Sørbye, Halfdan; Dahl, Olav. 2003. Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. Acta Oncologica. 827-831.
  • Sørbye, Halfdan; Dahl, Olav. 2003. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. Journal of Clinical Oncology. 4466-4467.
  • Øvrebø, Kjell Kåre; Aase, Steinar; Grong, Ketil; Viste, Asgaut; Svanes, Knut; Sørbye, Halfdan. 2002. Ulceration as a possible link between duodenogastric reflux and neoplasms in the stomach of rats. Journal of Surgical Research. 167-178.
  • Øvrebø, Kjell Kåre; Svanes, Knut; Aase, Steinar; Grong, Ketil; Kvinnsland, Steinar; Sørbye, Halfdan. 2002. Gastric mucosa lesions induced by duodenogastric reflux increase the penetration of N-[3H]-methyl-N-nitro-N-nitrosoguanidine into the corpus mucosa of rats. Digestive Diseases and Sciences. 2354-2369.
  • Øvrebø, Kjell Kåre; Svanes, Knut; Aase, Steinar Torbjørn; Grong, Ketil; Sørbye, Halfdan. 2002. Duodenogastric reflux increases the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the antral mucosa of rats. A possible role for mucosal erosions and increased cell proliferation in gastric carsinogenesis. Japanese Journal of Cancer Research. 484-494.
  • Sørbye, Halfdan; Bruserud, Øystein; Dahl, Olav. 2001. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. Acta Oncologica. 882-883.
  • Øvrebø, Kjell Kåre; Svardal, Asbjørn; Kvinnsland, Stener; Grong, Ketil; Svanes, Knut; Sørbye, Halfdan. 1999. Glutathione modulation changes the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. Digestive Diseases and Sciences. 2063-2075.
  • Sørbye, Halfdan; Jensen, Dag; Dahl, Olav. 1998. Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • Sørbye, Halfdan; Jensen, Dag; Dahl, Olav. 1998. Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • Øvrebø, Kjell Kåre; Sørbye, Halfdan; Kvinnsland, Stener; Grong, Ketil; Svanes, Knut. 1998. Effect of gastric secretion on the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. Digestive Diseases and Sciences. 2012-2020.
  • Øvrebø, Kjell Kåre; Sørbye, Halfdan; Svardal, Asbjørn; Grong, Ketil; Svanes, Knut. 1997. Glutathione and N-acetylcysteine reduce gastric mucosal blood flow in rats. Digestive Diseases and Sciences. 1765-1774.
  • Sørbye, Halfdan; Guttu, Kristian; Gislason, Hjørtur; Grong, Ketil; Svanes, Knut. 1993. Gastric mucosal injury and associated changes in mucosal blood flow and gastric fluid secretion caused by dimethyl sulphoxide (DMSO) in rats. Digestive Diseases and Sciences. 1243-1250.
Report
  • Aaserud, Morten; Kristiansen, Ivar Sønbø; Neilson, Aileen Rae; Norum, Jan; Sørbye, Halfdan; Aas, Eline; Gjertsen, Marianne Klemp. 2007. Health economic evaluation of bevacizumab for metastatic colorectal cancer. 23/2007. 23/2007. .
Academic lecture
  • Joranger, Pål; Nesbakken, Arild; Hoff, Geir; Sorbye, Halfdan; Oshaug, Arne; Aas, Eline. 2015. Modell for å beregne overlevelse og kostnader av behandling for kolorektal cancer.
  • Glimelius, Bengt; Sørbye, Halfdan; Balteskard, L; Byström, P; Pfeiffer, P; Tveit, KM; Heikkilä, R; Albertsson, M; Starkhammar, H; Dahl, Olav; Berglund, Å. 2005. A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer.
Editorial
  • Sorbye, Halfdan. 2012. Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used? Acta Oncologica. 819-821.
Reader opinion piece
  • Sorbye, Halfdan. 2019. Ekspertpanel for ny vurdering ved alvorlig sykdom. Tidsskrift for Den norske legeforening. 2 pages.
Short communication
  • Nordlinger, B; Gruenberger, T; Sørbye, Halfdan; Glimelius, Bengt. 2008. Surgery vs surgery and chemotherapy for colorectal liver metastases. The Lancet. 203.
Doctoral dissertation
  • Sørbye, Halfdan. 1994. Penetration of carcinogens into normal and damaged gastric mucosa.
Academic chapter/article/Conference paper
  • Sorbye, Halfdan. 2014. Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. 10 pages.
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Hoem, Dag; Postema, Michiel; Gjertsen, Bjørn Tore; Bjånes, Tormod Karlsen; Biermann, Martin; Mccormack, Emmet Martin; Sorbye, Halfdan; Molven, Anders; Gilja, Odd Helge. 2013. Ultrasound-assisted treatment of an inoperable pancreatic cancer.
  • Telhaug, Ragnar; Varhaug, Jan Erik; Sørbye, Halfdan; Bjøro, Trine; Haugen, Dagny Faksvåg; Gladhaug, Ivar P. 2009. Endokrine svulster.
  • Sørbye, Halfdan. 2008. The use of Chemotherapy for Neuroendocrine Tumors.
  • Bremnes, RM; Endresen, P; Sørbye, Halfdan. 1999. Antimetabolitter.
Abstract
  • Pfeiffer, Per; Glimelius, Bengt; Winther, Stine Brændegaard; Qvortrup, Camilla; Yilmaz, Mette Karen Nytoft; Berglund, Åke; Vistisen, Kirsten Kjeldgaard; Kersten, Christian; Liposits, Gabor Isivan; Sorbye, Halfdan. 2019. Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. Annals of Oncology. iv131-iv131.
  • Hamfjord, Julian; Guren, Tormod Kyrre; Dajani, Olav; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per; Christoffersen, Thoralf; Lingjærde, Ole Christian; Tveit, Magne Kjell; Kure, Elin Wenche Hegland; Pallisgaard, Niels; Spindler, Karen-Lise Garm. 2018. Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy. Annals of Oncology. v109-v109.
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology.
  • Sorbye, Halfdan; Welin, Staffan; Langer, Seppo; Vestermark, Lena; Holt, Nanna; Osterlund, Pia; Dueland, Svein; Hofsli, Eva; Guren, Marianne; Ohrling, Katarina; Birkemeyer, Elke; Thiis-Evensen, Espen; Biagini, Matteo; Gronbaek, Henning; Soveri, Leena-Maija; Olsen, Ingrid Holst; Federspiel, Birgitte; Assmuss, Jørg; Janson, Eva T.; Knigge, Ulrich. 2013. Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3). Pancreas. 382-382.
  • Sorbye, Halfdan; Welin, Staffan; Langer, Seppo W.; Vestermark, Lene Weber; Holt, Nanna; Osterlund, Pia J.; Dueland, Svein; Hofsli, Eva; Guren, Marianne; Ohrling, Katarina; Birkemeyer, Elke; Thiis-Evensen, Espen; Biagini, Matteo; Grønbæk, Henning; Soveri, Leena-Marja; Olsen, Ingrid Holst; Federspiel, Birgitte; Assmus, Jørg; Janson, Eva Tiensuu; Knigge, Ulrich. 2012. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. Journal of Clinical Oncology. 1 pages.
  • Tarpgaard, Line Schmidt; Guren, Tormod Kyrre; Glimelius, Bengt; Pfeiffer, Per; Kure, Elin; Yilmaz, Mette Karen; Sorbye, Halfdan; Keldsen, Nina; Skovlund, Eva; Johansen, Julia S.; Tveit, Magne Kjell. 2012. Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study. Journal of Clinical Oncology. 1 pages.
  • Pfeiffer, Per; Sorbye, Halfdan; Qvortrup, Camilla; Karlberg, Mia; Naucler, Gisela; Kersten, Christian; Vistisen, Kirsten; Lindh, Birgitta; Glimelius, Bengt. 2012. Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. Journal of Clinical Oncology. 1 pages.
  • Nordlinger, Bernard; Sorbye, Halfdan; Glimelius, Bengt; Poston, Graeme John; Schlag, Peter M.; Rougier, Philippe; Bechstein, Wolf O.; Primrose, John N.; Walpole, Euan Thomas; Finch-Jones, Meg; Jaeck, Daniel; Mirza, Darius; Parks, Rowan W.; Collette, Laurence; Praet, Michel; Van Cutsem, Eric; Scheithauer, Werner; Mauer, Murielle E.; Gruenberger, Thomas. 2012. Long term survival data from EORTC Study 40983:perioperative chemotherapy for resectable liver metastasesfrom colorectal cancer. Annals of Oncology. 18-18.
  • Nordlinger, Bernard; Sorbye, Halfdan; Glimelius, Bengt; Poston, Graeme John; Schlag, Peter M.; Rougier, Philippe; Bechstein, Wolf; Primrose, John Neil; Walpole, Euan Thomas; Mauer, Murielle E.; Gruenberger, Thomas. 2012. EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. Journal of Clinical Oncology. 1 pages.
  • Qvortrup, C; Cvancarova, M; Glimelius, B.; Pfeiffer, P; Sorbye, Halfdan. 2012. AGE DEPENDENT INCREASE IN MEDIAN AND LONG-TERM SURVIVAL IN 29 628 METASTATIC COLORECTAL CANCER (MCRC) SCANDINAVIAN PATIENTS DURING THE PAST TWO DECADES. Annals of Oncology. 188-188.
  • Tveit, Magne Kjell; Guren, Tormod Kyrre; Glimelius, Bengt; Pfeiffer, P; Sørbye, Halfdan; Pyrhönen, S; Kure, Elin H.; Ikdahl, Tone; Skovlund, Eva; Christoffersen, Thoralf. 2010. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the Nordic VII study (NCT00145314), by the Nordic colorectal cancer biomodulation group. Annals of Oncology. 9-9.
  • Gruenberger, T; Sørbye, Halfdan; Debois, M; Bethe, U.; Primrose, J.; Rougier, P.; Jaeck, D.; Finch-Jones, M.; Van Cutsem, E.; Nordlinger, B. 2006. Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology. 146S-146S.
  • Nordlinger, B; Sørbye, Halfdan; Debois, M; Praet, M; Glimelius, Bengt; Poston, GJ; Schlag, PM; Walpole, ET; Bechstein, W; Gruenberger, T. 2005. Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology. 253S-253S.
Poster
  • Joranger, Pål; Nesbakken, Arild; Hoff, Geir; Sorbye, Halfdan; Oshaug, Arne; Aas, Eline. 2014. Development and validation of a Norwegian model for colorectal cancer.
  • Sørbye, Halfdan; Glimelius, Bengt; Berglund, Åke; Fokstuen, Tone; Tveit, Kjell Magne; Brændengen, Morten; Øgreid, Dagfinn; Dahl, Olav. 2003. Nordic 5-fluorouracil/folinic acid bolus schedule combined with oxaliplatin (FLOX) as first-line treatment to metastatic colorectal cancer.
Errata
  • Lutz, Manfred P.; Zalcberg, John R.; Glynne-Jones, Rob; Ruers, Theo; Ducreux, Michel; Arnold, Dirk; Aust, Daniela; Brown, Gina; Bujko, Krzysztof; Cunningham, Christopher; Evrard, Serge; Folprecht, Gunnar; Gerard, Jean-Pierre; Habr-Gama, Angelita; Haustermans, Karin; Holm, Torbjörn; Kuhlmann, Koert F.; Lordick, Florian; Mentha, Gilles; Moehler, Markus; Nagtegaal, Iris D.; Pigazzi, Alessio; Pucciarelli, Salvatore; Roth, Arnaud; Rutten, Harm; Schmoll, Hans-Joachim; Sorbye, Halfdan; Van Cutsem, Eric; Weitz, Jürgen; Otto, Florian. 2016. Erratum: Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" (European Journal of Cancer (2016) 68 (208?209) (S0959804916320780) (10.1016/j.ejca.2016.04.010)). European Journal of Cancer. 208-209.
Academic literature review
  • Sorbye, Halfdan; Kong, Grace; Grozinsky-Glasberg, Simona. 2020. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). R67-R77.
  • Goey, Kaitlyn K.H.; Mahmoud, Remi; Sorbye, Halfdan; Glimelius, Bengt; Köhne, Claus Henning; Sargent, Daniel J.; Punt, Cornelis J.A.; van Oijen, Martijn G.H.; Koopman, Miriam. 2018. Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. 115-124.
  • Lutz, Manfred P.; Zalcberg, John R.; Glynne-Jones, Rob; Ruers, Theo; Ducreux, Michel; Arnold, Dirk; Aust, Daniela; Brown, Gina; Bujko, Krzysztof; Cunningham, Christopher; Evrard, Serge; Folprecht, Gunnar; Gerard, Jean-Pierre; Habr-Gama, Angelita; Haustermans, Karin; Holm, Torbjörn; Kuhlmann, Koert F; Lordick, Florian; Mentha, Gilles; Moehler, Markus; Nagtegaal, Iris D.; Pigazzi, Alessio; Puciarelli, Salvatore; Roth, Arnaud; Rutten, Harm; Schmoll, Hans-Joachim; Sorbye, Halfdan; Van Cutsem, Eric; Weitz, Jürgen; Otto, Florian. 2016. Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer. 11-24.
  • Sorbye, Halfdan; Strosberg, Jonathan; Baudin, Eric; Klimstra, David S.; Yao, James C. 2014. Gastroenteropancreatic high-grade neuroendocrine carcinoma. 2814-2823.
  • Biermann, Martin; Johnsen, Boel; Sørbye, Halfdan; Følling, Magne; Sundin, Anders; Bach-Gansmo, Ingolv Tore. 2009. Positronemisjonstomografi ved nevroendokrine svulster. 1474-1477.
  • Sørbye, Halfdan; Brændengen, M; Balteskard, L. 2008. Palliativ kjemoterapi og strålebehandling ved metastatisk kolorectalkreft. 194-197.

More information in national current research information system (CRIStin)